
    
      A double-blind, randomized clinical trial of three pharmacological groups in 33 patients with
      a diagnosis of grade 1 obesity in accordance with the World Health Organization (WHO) without
      treatment.

      They will be assigned randomly three groups of 11 patients, each one will receive 10 mg of
      dapaglizflozin (Forxiga, Astra Zeneca), 1000 mg of metformin XR or 10/1000 mg of
      dapagliflozin plus metformin XR, one time per day before having break-fast during 12 weeks.

      The body weight, body mass index (BMI), adiposity %, visceral adiposity, fat mass, lean mass,
      waist circunference,waist-hip index, arterial pressure, and laboratory parameters as a
      glucose, triglicerides, cholesterol, High density lipoprotein (c-HDL), low density
      lipoprotein (c-LDL), uric acid, creatinin, C reactive protein, adiponectin and interleukin
      10, leptin and TNF-∝will be measures.

      This protocol is already approved by the local ethics committee and written informed consent
      it's going to be obtained from all volunteers.

      Statistical analysis will be presented through measures of central tendency and dispersion,
      average and deviation standard for quantitative variables; frequencies and percentages for
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for
      differences inter-group Kruskal-Wallis Test and Wilcoxon Test for the within-groups
      differences. It will be considered statistical significance p ≤0.05.
    
  